A Randomized, Open-label, 2-Way-Crossover Study Assessing the Bioequivalence Between Single Doses of 500 mg Glucophage® XR RM Tablets (Merck/China Jiangsu-Manufactured) and 500 mg Glucophage® XR RM Tablets (Merck/Germany Darmstadt-Manufactured) Under Fed and Fasted State in Healthy Participants
Latest Information Update: 18 Apr 2023
At a glance
- Drugs Metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Merck KGaA
Most Recent Events
- 13 Apr 2023 Status changed from recruiting to completed.
- 10 Aug 2022 Status changed from not yet recruiting to recruiting.
- 21 Jul 2022 New trial record